Metabolism


Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
-
B5697 WIN 18446Summary: inhibitor of aldehyde dehydrogenase 1a2 (ALDH1a2) -
A4334 Avanafil1 CitationTarget: Phosphodiesterases (PDEs)Summary: PDE5 inhibitor -
A4357 Dorzolamide HClSummary: Carbonic anhydrase inhibitor -
C5081 Bromoenol lactoneSummary: Inhibitor of myocardial cytosolic calcium-independent phospholipase A2 (iPLA2) -
C4131 SulfaphenazoleSummary: CYP2C9 inhibitor -
B2117 Pioglitazone1 CitationSummary: PPAR agonist -
B5462 Rotenone9 CitationTarget: complex I of the mitochondrial electron transport chainSummary: mitochondrial Complex I inhibitor -
A4304 Rosiglitazone4 CitationSummary: Potent PPARγ agonist -
A4601 Empagliflozin (BI 10773)2 CitationSummary: SGLT-2 inhibitor for oral treatment of type 2 diabetes -
A5143 FinasterideSummary: Inhibitor of Type II 5α-reductase

